Physician profile
Nancy J Hampton-Jones
NPI 1881001535
$4,601.83
in general payments reported to CMS, 2019-2025
38 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what 91% of Clinical Nurse Specialist providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $401 · 2022: $675 · 2023: $1,412 · 2024: $890 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,958 · Education: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,958.45 |
| Education | $566.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $569.20 | 2022-2025 | Opdivo, Reblozyl |
| Gilead Sciences, INC. | $399.33 | 2023-2025 | Trodelvy |
| Janssen Biotech, INC. | $353.16 | 2023-2025 | Rybrevant, Carvykti, Balversa |
| Genzyme Corporation | $343.92 | 2021-2023 | |
| G1 Therapeutics, INC. | $242.92 | 2022-2023 | Cosela |
| Takeda Pharmaceuticals U.S.A., INC. | $235.27 | 2022-2023 | Iclusig, Ninlaro |
| Abbvie INC. | $232.96 | 2024-2025 | |
| Amgen INC. | $205.51 | 2022-2023 | Lumakras, Xgeva, Nplate |
| Astrazeneca Pharmaceuticals LP | $194.28 | 2023-2025 | Imfinzi, Lynparza |
| Daiichi Sankyo INC. | $158.58 | 2022-2024 | Enhertu |
| Rigel Pharmaceuticals, INC. | $141.72 | 2023 | Rezlidhia, Tavalisse |
| Seagen INC. | $130.14 | 2023-2025 | Adcetris |
| Astellas Pharma US INC | $124.99 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $111.39 | 2022-2025 | Libtayo |
| Genentech USA, INC. | $102.97 | 2021-2023 | Venclexta |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Hampton-Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.